CA2631430C - Epidermal growth factor receptor binding polypeptides - Google Patents

Epidermal growth factor receptor binding polypeptides Download PDF

Info

Publication number
CA2631430C
CA2631430C CA2631430A CA2631430A CA2631430C CA 2631430 C CA2631430 C CA 2631430C CA 2631430 A CA2631430 A CA 2631430A CA 2631430 A CA2631430 A CA 2631430A CA 2631430 C CA2631430 C CA 2631430C
Authority
CA
Canada
Prior art keywords
ala
leu
asn
egfr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2631430A
Other languages
English (en)
French (fr)
Other versions
CA2631430A1 (en
Inventor
Fredrik Nilsson
Tove Eriksson
Andreas Jonsson
Stefan Stahl
Mikaela Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of CA2631430A1 publication Critical patent/CA2631430A1/en
Application granted granted Critical
Publication of CA2631430C publication Critical patent/CA2631430C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2631430A 2005-12-05 2006-12-05 Epidermal growth factor receptor binding polypeptides Active CA2631430C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0524788.7 2005-12-05
GBGB0524788.7A GB0524788D0 (en) 2005-12-05 2005-12-05 Polypeptides
PCT/EP2006/011669 WO2007065635A1 (en) 2005-12-05 2006-12-05 Polypeptides

Publications (2)

Publication Number Publication Date
CA2631430A1 CA2631430A1 (en) 2007-06-14
CA2631430C true CA2631430C (en) 2017-03-07

Family

ID=35686099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2631430A Active CA2631430C (en) 2005-12-05 2006-12-05 Epidermal growth factor receptor binding polypeptides

Country Status (9)

Country Link
US (3) US8247375B2 (cg-RX-API-DMAC10.html)
EP (2) EP1973934B1 (cg-RX-API-DMAC10.html)
JP (2) JP5898826B2 (cg-RX-API-DMAC10.html)
CN (2) CN101336250A (cg-RX-API-DMAC10.html)
CA (1) CA2631430C (cg-RX-API-DMAC10.html)
DK (1) DK2431383T3 (cg-RX-API-DMAC10.html)
ES (1) ES2599996T3 (cg-RX-API-DMAC10.html)
GB (1) GB0524788D0 (cg-RX-API-DMAC10.html)
WO (1) WO2007065635A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
EA021967B1 (ru) * 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US9238810B2 (en) 2008-06-05 2016-01-19 Affibody Ab Polypeptide
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
EP2728000B1 (en) * 2011-06-03 2018-12-05 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
WO2014053586A1 (en) 2012-10-05 2014-04-10 Affibody Ab Her3 binding polypeptides
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
PT3604333T (pt) 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
KR20240110106A (ko) 2015-01-12 2024-07-12 애피바디 에이비 Il-17a-결합 폴리펩티드
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
US10521754B2 (en) * 2016-03-08 2019-12-31 Auctane, LLC Concatenated shipping documentation processing spawning intelligent generation subprocesses
CN111925425B (zh) * 2020-08-12 2023-03-10 天津科技大学 甲胎蛋白特异性结合多肽及应用
JP2025507294A (ja) * 2022-02-04 2025-03-18 ザイトックス セラピューティクス アクチボラゲット Ｅｇｆｒ結合ドメインとマスキングドメインとを含む融合タンパク質
CN119677787A (zh) 2022-08-10 2025-03-21 兴和株式会社 亲和体微胞药物复合体
CN117106035B (zh) * 2023-10-25 2024-04-23 烟台药物研究所 一种肿瘤靶向多肽、多肽偶联药物及制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
SE0301936D0 (sv) 2003-06-30 2003-06-30 Affibody Ab New polypeptide
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
AU2005233843A1 (en) * 2004-04-16 2005-10-27 Hidetoshi Okabe Method of examining malignant tumor

Also Published As

Publication number Publication date
CN103288935A (zh) 2013-09-11
JP5898826B2 (ja) 2016-04-06
EP2431383B1 (en) 2016-09-28
US20140178301A1 (en) 2014-06-26
WO2007065635A1 (en) 2007-06-14
EP1973934B1 (en) 2014-11-05
CN103288935B (zh) 2017-11-17
JP2014087361A (ja) 2014-05-15
GB0524788D0 (en) 2006-01-11
US20090016957A1 (en) 2009-01-15
EP2431383A1 (en) 2012-03-21
US9107965B2 (en) 2015-08-18
DK2431383T3 (en) 2017-01-09
CN101336250A (zh) 2008-12-31
US8247375B2 (en) 2012-08-21
CA2631430A1 (en) 2007-06-14
US8598113B2 (en) 2013-12-03
ES2599996T3 (es) 2017-02-06
EP1973934A1 (en) 2008-10-01
US20130005653A1 (en) 2013-01-03
JP2009519013A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
US8598113B2 (en) Polypeptides
Friedman et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor
CA2531238C (en) Polypeptides having binding affinity for her2
JP5960598B2 (ja) Ｈｅｒ３結合ポリペプチド
US8426557B2 (en) IGF-1R binding polypeptides and their use
KR102191655B1 (ko) Her3 결합 폴리펩티드
EP4424703A1 (en) Polypeptides for transferrin receptor-mediated transcytosis
HK1125657A (zh) 多肽
HK1186197A (en) Polypeptides
HK1186197B (zh) 多肽
CN114829388A (zh) 抗her2多肽衍生物作为新的诊断分子探针
JP2024506070A (ja) 新規ｈｅｒ２結合ポリペプチド
CN115244073B (zh) 抗her2多肽衍生物作为新的诊断分子探针
TW202545983A (zh) 新穎多肽
CN118459549A (zh) 靶向表皮生长因子受体的多肽
HK1207657B (en) Her3 binding polypeptides

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250605

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106